
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 319 - 319
Published: March 1, 2025
Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals therapeutic indications, there are challenges minimizing risks interactions between cannabis-based products, prescription drugs, other approved substances of abuse. Thus, identifying enzymes metabolizing cannabinoid drugs their relationship crucial for understanding potential effects simultaneous use. This article offers a comprehensive review pharmacokinetic as well It also compiles existing evidence these describes clinical outcomes associated inhibition or induction various enzymes.
Language: Английский